Monotherapy treatment with PI3Kα/δ inhibitors reduces growth of ABC-DLBCL cell lines and tumour models, whilst monotherapy AKT inhibition in effective in PTEN null GCB DLBCL [7, 9]. The gene discussed is PTEN; the disease is diffuse large B-cell lymphoma.